At the time of writing, Insight Molecular Diagnostics Inc [IMDX] stock is trading at $7.5, up 7.14%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The IMDX shares have gain 38.63% over the last week, with a monthly amount glided 30.21%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Insight Molecular Diagnostics Inc [NASDAQ: IMDX] stock has seen the most recent analyst activity on March 28, 2025, when Lake Street initiated its Buy rating and assigned the stock a price target of $5. Previously, Stephens downgraded its rating to Equal-Weight on May 24, 2022. On March 14, 2022, downgrade downgraded it’s rating to Sector Weight. Stephens started tracking the stock assigning a Overweight rating and suggested a price target of $3.10 on January 07, 2022. In a note dated January 07, 2021, The Benchmark Company upgraded an Buy rating on this stock but restated the target price of $6.
For the past year, the stock price of Insight Molecular Diagnostics Inc fluctuated between $1.92 and $8.51. Currently, Wall Street analysts expect the stock to reach $9 within the next 12 months. Insight Molecular Diagnostics Inc [NASDAQ: IMDX] shares were valued at $7.5 at the most recent close of the market. An investor can expect a potential return of 20.0% based on the average IMDX price forecast.
Analyzing the IMDX fundamentals
According to Insight Molecular Diagnostics Inc [NASDAQ:IMDX], the company’s sales were 4.40M for trailing twelve months, which represents an 126.09% jump. Gross Profit Margin for this corporation currently stands at 0.63% with Operating Profit Margin at -14.98%, Pretax Profit Margin comes in at -14.9%, and Net Profit Margin reading is -14.9%. To continue investigating profitability, this company’s Return on Assets is posted at -1.26, Equity is -28.98 and Total Capital is -1.45. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 3.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.14 points at the first support level, and at 6.77 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.69, and for the 2nd resistance point, it is at 7.87.
Ratios To Look Out For
It is important to note that Insight Molecular Diagnostics Inc [NASDAQ:IMDX] has a current ratio of 2.79. Also, the Quick Ratio is 2.73, while the Cash Ratio stands at 3.65. Considering the valuation of this stock, the price to sales ratio is 48.86.
Transactions by insiders
Recent insider trading involved James Andrea S., Chief Financial Officer, that happened on Feb 07 ’25 when 97561.0 shares were purchased. 10% Owner, SMITH PATRICK W completed a deal on Feb 07 ’25 to buy 1.08 million shares. Meanwhile, 10% Owner BROADWOOD PARTNERS, L.P. bought 5.17 million shares on Feb 06 ’25.
